Types and risk groups of Hodgkin lymphoma: what changes treatment

Risk groups in Hodgkin lymphoma are primarily tools for choosing treatment. They help clinicians consider how much initial therapy is appropriate, whether radiation belongs in the plan, when PET should be assessed, and where treatment exposure might safely be reduced. A “high-risk” label describes features shared by a group of patients; it does not establish an individual lifespan or make the outcome certain.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted are microscopic patterns within classical Hodgkin lymphoma. They do not function as independent prescriptions. Two patients with different histological subtypes may appropriately receive the same regimen, while two with the same subtype may need different treatment because their stage or health differs. The subtype name alone is not a reason to request the most intensive program. [S8]
Higher disease risk makes selection of effective therapy particularly important, but additional treatment can also increase marrow suppression, infection, reproductive harm, or organ toxicity. The task is to weigh those risks together, not automatically add drugs whenever a higher-risk label appears. Existing heart disease, lung disease, neuropathy, and substantial infection history should be disclosed before choosing a regimen. [S1]
A useful review includes original pathology, baseline imaging, involved sites, symptom history, and recent laboratory findings. If treatment has started, provide exact dates, drugs, doses, and adjustments. Ask the receiving team to state the pathological category, risk framework, specific factors supporting the classification, and resulting treatment recommendation. This allows meaningful comparison between centers using the same underlying facts.

Quick answer

Full guide

Three questions should be kept distinct: which pathological disease is present, what clinical risk its distribution and symptoms create, and what treatment the person can tolerate. These do not always point in the same direction. A younger person with extensive disease may tolerate curative treatment well, while an older person with limited disease may need careful modifications for other health problems.

Classical Hodgkin lymphoma includes several tissue patterns

Nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted are microscopic patterns within classical Hodgkin lymphoma. They do not function as independent prescriptions. Two patients with different histological subtypes may appropriately receive the same regimen, while two with the same subtype may need different treatment because their stage or health differs. The subtype name alone is not a reason to request the most intensive program. [S8]

Histology can be associated with particular clinical settings, but treatment decisions also depend on disease extent, bulk, symptoms, and response. Modern trials often enroll classical Hodgkin lymphoma according to early or advanced disease criteria rather than selecting treatment solely by its microscopic subtype. Include the full pathology name in a consultation summary and ask what effect, if any, that subtype has on the decision being made. [S2]

Nodular lymphocyte-predominant disease needs separate consideration

Nodular lymphocyte-predominant disease differs from classical Hodgkin lymphoma in its pathological features, markers, and clinical behavior. Some classifications use the name nodular lymphocyte-predominant B-cell lymphoma. Selected patients with limited, low-burden disease may be considered for local radiation, another less intensive approach, or observation, while symptomatic or more extensive disease requires different discussion. [S1]

Observation requires a secure diagnosis, appropriate selection, and a follow-up arrangement that can actually be delivered. It is not evidence that a person with active classical Hodgkin lymphoma can safely wait indefinitely. Transformation to an aggressive B-cell lymphoma can occur in lymphocyte-predominant disease. A change in growth pattern or new symptoms may make repeat tissue sampling important rather than simply continuing to rely on the original diagnosis. [S2]

The name is also easily confused with lymphocyte-rich classical Hodgkin lymphoma. If the consultation discusses rituximab-based treatment alongside classical Hodgkin regimens, clarify which pathological entity is being addressed. A patient should not independently assign the disease category from CD20 staining alone.

Early stage and favorable risk are not synonyms

Stage I or II classical disease is often subdivided into favorable and unfavorable categories. Factors may include a large mediastinal mass, extranodal disease, inflammatory markers, the number of involved regions, and systemic symptoms. Different study groups use somewhat different definitions. A clinician describing “early unfavorable” disease should be able to identify the findings that place the patient in that group. [S23]

This distinction can influence chemotherapy exposure, radiotherapy, and whether a specific PET-adapted reduction is supported. When two regimens both claim to treat stage II disease but differ in intensity, first check whether they refer to the same risk definition. Another patient's course may omit a treatment because that person did not have the bulky mass or other factor present in your case.

Advanced disease still needs an individual assessment

Advanced classical Hodgkin lymphoma involves broader lymphatic distribution or relevant organ involvement. Baseline clinical and laboratory features may help estimate disease risk and inform systemic treatment selection. Traditional prognostic scores were developed in particular treatment eras. Their historical outcome estimates should not be directly applied to an individual receiving contemporary treatment and supportive care. [S1]

Discussions of nivolumab-AVD, brentuximab vedotin-AVD, ABVD, or a PET-guided intensive approach must also consider cardiac, pulmonary, neurologic, immune, and infection issues. There is no single ranking that is correct for every person with advanced disease. Patients with the same stage can reasonably receive different treatment because their health and treatment constraints differ. [S2][S6]

Describe bulky disease in practical terms

A large mediastinal mass can affect breathing, venous return, or anesthesia planning. A large lesion elsewhere may compress nearby structures. The assessment should therefore record location, measurements, and actual symptoms, not just the word “bulky.” New difficulty breathing, face or neck swelling, or inability to lie flat requires timely clinical evaluation rather than waiting for the next routine risk-group discussion.

Bulk may also affect radiation planning and interpretation of residual tissue after treatment. A large original mass can leave a visible remnant without the entire remnant representing active lymphoma. Metabolic response and the treatment pathway help determine its significance. Keeping the original images allows different teams to assess the same starting point rather than relying only on a final measurement. [S28]

Disease risk and treatment risk need separate answers

Higher disease risk makes selection of effective therapy particularly important, but additional treatment can also increase marrow suppression, infection, reproductive harm, or organ toxicity. The task is to weigh those risks together, not automatically add drugs whenever a higher-risk label appears. Existing heart disease, lung disease, neuropathy, and substantial infection history should be disclosed before choosing a regimen. [S1]

Chronological age is also incomplete. Day-to-day independence, nutrition, cognition, falls, comorbidity, and available support affect whether treatment can be completed. An independent older adult and a person of similar age who needs extensive daily care should not receive identical assumptions about tolerance. If treatment is modified, the team should explain which components change, why, and what goal remains realistic.

Practical treatment risk includes the ability to obtain urgent care between infusions. A person living several hours from a hospital may need different arrangements for blood tests, fever evaluation, or temporary accommodation. Those arrangements do not change the pathological disease, but can influence whether a proposed course is deliverable.

Fertility risk is not part of the stage label

Reproductive effects depend on the drugs, cumulative exposure, age, and pretreatment function. The fertility analysis of HD21 compared gonadal recovery following BrECADD and escalated BEACOPP, providing information relevant to regimen discussions. Hormonal recovery outcomes cannot guarantee that an individual will later conceive naturally or become a parent. [S27]

Even if the initial risk group permits a regimen with comparatively less reproductive toxicity, discuss preservation before treatment when possible. The plan may change if response is inadequate, and later therapy can bring different risks. Asking separately about fertility effects of the initial course and possible future treatment can help decide whether an early reproductive-medicine consultation is worthwhile. [S10][S11]

Response can update the risk assessment

Risk is not assessed only on the day of diagnosis. Interim PET shows how disease is responding to the current program and can guide subsequent therapy within an evidence-based pathway. RATHL supports modification of bleomycin exposure in selected patients beginning ABVD for advanced disease, illustrating how observed response can refine decisions made from baseline information. [S5]

Low baseline risk cannot guarantee a negative interim PET, and a negative PET does not mean the rest of treatment can be abandoned. The clinician should specify the assessment time, scoring threshold, and exact treatment components retained or omitted. Unplanned dose reduction is not equivalent to a trial-supported response-adapted strategy.

When discussing a change, ask whether it reflects disease response, toxicity, a new diagnostic finding, or a practical limitation. These reasons have different implications. A drug stopped because of lung toxicity, for example, should not automatically be restarted at another center merely because the original regimen name remains on the referral.

Children and adolescents require age-appropriate pathways

Pediatric and adolescent protocols account for growth, development, and long-term exposure. Their risk categories and how they are used may differ from adult programs. Radiation decisions, drug exposure, and later screening can have age-specific features. A patient near the boundary between pediatric and adult services should know which team and complete protocol are responsible for care. [S29]

The FDA's 2026 nivolumab-AVD approval includes patients aged 12 years and older with previously untreated stage III or IV classical disease. It does not mean that every child above that age should receive the same treatment, and it does not establish a Chinese indication. Pathology, stage, pediatric practice, other health conditions, and current local authorization still require assessment. [S3]

Use the risk label to ask actionable questions

Hearing “high risk” can make a patient reluctant to plan for the future, or lead relatives to request more treatment regardless of its consequences. Replace the broad label with specific questions: what difficulty does this factor increase, which option addresses it, what additional harm could that option cause, and when will the team know whether treatment is working? These questions connect the assessment to decisions that can be made.

Lower risk does not eliminate treatment side effects or the need for follow-up. Later care should reflect actual heart, lung, thyroid, reproductive, and other relevant exposures. A survivorship plan should document the treatment received and the problems experienced, rather than simply saying “low risk, routine review.” [S13]

Obtaining a second opinion in China

A useful review includes original pathology, baseline imaging, involved sites, symptom history, and recent laboratory findings. If treatment has started, provide exact dates, drugs, doses, and adjustments. Ask the receiving team to state the pathological category, risk framework, specific factors supporting the classification, and resulting treatment recommendation. This allows meaningful comparison between centers using the same underlying facts.

Check the proposed drug's treatment setting and current Chinese product information separately. Several PD-1 indications in the official 2025 guidance concern relapsed or refractory classical disease after specified previous systemic treatment. Being described as “high risk” does not by itself satisfy a later-line indication. If another prescribing route or a clinical study is proposed, evidence, payment, and consent arrangements should be explained. [S7]

Travel is most useful when it resolves a pathology question, a genuine risk-classification disagreement, or an important treatment choice. Searching for a more reassuring label alone may not improve care. Where the existing evidence already supports a clear and feasible plan, completing that plan can be more valuable than repeatedly changing the terminology used to describe the risk.